Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Early Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT02625935
What this trial is testing

Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients

Who this might be right for
Breast Cancer
NanoString Technologies, Inc. 206
Large-scale testing (Phase 3)Study completedNCT01940497
What this trial is testing

The Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 240
Testing effectiveness (Phase 2)Study completedNCT02132949
What this trial is testing

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 401
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07317778
What this trial is testing

Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)HR Positive/HER2 Low Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 249
Not applicableStudy completedNCT05599334
What this trial is testing

A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib

Who this might be right for
Breast CancerAdjuvant TherapyHER2-positive Breast Cancer
Pierre Fabre Medicament 111
Not applicableStudy completedNCT07072013
What this trial is testing

An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 1,937
Testing effectiveness (Phase 2)Study completedNCT00148668
What this trial is testing

Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Eric Winer, MD 81
Not applicableStudy completedNCT02773004
What this trial is testing

Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer

Who this might be right for
Breast Cancer
UNICANCER 203
Testing effectiveness (Phase 2)WithdrawnNCT04419181
What this trial is testing

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
University of Rochester
Large-scale testing (Phase 3)Study completedNCT03989037
What this trial is testing

SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer

Who this might be right for
HER2-positive Early Breast Cancer
Shanghai Institute Of Biological Products 580
Testing effectiveness (Phase 2)Study completedNCT01401166
What this trial is testing

Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Who this might be right for
Breast Neoplasms
Hoffmann-La Roche 488
Not applicableUnknownNCT05491057
What this trial is testing

Treatment Patterns of Neratinib in HER2+ EBC in China

Who this might be right for
Breast Cancer
Pierre Fabre Medicament 500
Large-scale testing (Phase 3)Study completedNCT01901146
What this trial is testing

Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer

Who this might be right for
Breast Cancer
Amgen 725
Testing effectiveness (Phase 2)Looking for participantsNCT04750122
What this trial is testing

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients

Who this might be right for
HER2-positive Early Breast Cancer
Peking University People's Hospital 46
Testing effectiveness (Phase 2)Looking for participantsNCT06517212
What this trial is testing

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmsBreast Cancers
Baylor Research Institute 48
Testing effectiveness (Phase 2)Looking for participantsNCT05020860
What this trial is testing

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmBreast Cancer Female+8 more
Baylor Breast Care Center 185
Not applicableLooking for participantsNCT06650423
What this trial is testing

Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

Who this might be right for
Early Breast CancerHormone Receptor Positive TumorHER2-negative Breast Cancer
Institute of Oncology Ljubljana 319
Testing effectiveness (Phase 2)Active Not RecruitingNCT06394661
What this trial is testing

Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Henan Cancer Hospital 109
Testing effectiveness (Phase 2)Ended earlyNCT01919229
What this trial is testing

A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)

Who this might be right for
Early Breast Cancer
Novartis Pharmaceuticals 14
Not applicableActive Not RecruitingNCT03904173
What this trial is testing

Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmsHormone Receptor Positive Tumor
Oslo University Hospital 2,300
Next Page